- Home
- ATHA vs SABS Comparison
ATHA vs SABS Comparison
Compare ATHA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- SABS
- Stock Information
- Founded
- ATHA 2011
- SABS 2014
- Country
- ATHA United States
- SABS United States
- Employees
- ATHA N/A
- SABS N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- SABS Health Care
- Exchange
- ATHA Nasdaq
- SABS Nasdaq
- Market Cap
- ATHA 14.8M
- SABS 15.8M
- IPO Year
- ATHA 2020
- SABS N/A
- Fundamental
- Price
- ATHA $0.36
- SABS $2.12
- Analyst Decision
- ATHA Hold
- SABS Strong Buy
- Analyst Count
- ATHA 3
- SABS 4
- Target Price
- ATHA $0.50
- SABS $9.50
- AVG Volume (30 Days)
- ATHA 159.8K
- SABS 84.0K
- Earning Date
- ATHA 11-06-2025
- SABS 11-05-2025
- Dividend Yield
- ATHA N/A
- SABS N/A
- EPS Growth
- ATHA N/A
- SABS N/A
- EPS
- ATHA N/A
- SABS N/A
- Revenue
- ATHA N/A
- SABS $114,698.00
- Revenue This Year
- ATHA N/A
- SABS N/A
- Revenue Next Year
- ATHA N/A
- SABS N/A
- P/E Ratio
- ATHA N/A
- SABS N/A
- Revenue Growth
- ATHA N/A
- SABS N/A
- 52 Week Low
- ATHA $0.22
- SABS $1.00
- 52 Week High
- ATHA $0.83
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- ATHA 36.59
- SABS 47.01
- Support Level
- ATHA $0.35
- SABS $2.03
- Resistance Level
- ATHA $0.40
- SABS $2.34
- Average True Range (ATR)
- ATHA 0.02
- SABS 0.11
- MACD
- ATHA -0.00
- SABS -0.00
- Stochastic Oscillator
- ATHA 11.86
- SABS 29.03
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.